[Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma]. 1981

L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov

A randomized cooperative study comparing 2 regimens of chemotherapy (DTIC--150mg/m2 iv days 1, 2, 3, 4, 5 and a combination of vincristine--1.4 mg/m2 iv days 1, 8, 15, nitrosomethylurea--200 mg/m2 iv days 3, 5, 10, 12 and dactinomycin--0.3 mg/m2 iv days 1, 3, 5, 8, 10, 12) was carried out in 114 patients with disseminated skin melanoma. A combined chemotherapy course given to 58 patients was followed by complete response (CR) in 8 cases (13.7%) and partial response by over 50% (PR)--in 6 cases (10.4%). In 56 patients treated with DTIC, CR was registered in 4 patients (7.1%) and PR in 9 (16%). Patients resistant to one regimen did not respond to the other.

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008770 Methylnitrosourea A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties. Nitrosomethylurea,N-Methyl-N-nitrosourea,NSC-23909,N Methyl N nitrosourea,NSC 23909,NSC23909
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
October 1973, Cancer,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
January 1977, Cancer,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
January 1977, Cancer,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
January 1977, Cancer,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
June 1976, Clinical pharmacology and therapeutics,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
January 1991, Voprosy onkologii,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
January 1986, Archiv fur Geschwulstforschung,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
August 1980, Cancer,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
January 1973, Voprosy onkologii,
L M Kogoniia, and L V Moroz, and N I Perevodchikova, and L V Platinskiĭ, and A I Borisov
May 1977, Cancer,
Copied contents to your clipboard!